Skip to main content
TipRanks
Go Ultimate75% OFF

Skye Bioscience (SKYE) Q3 2025 Earnings Report

1,005 Followers

SKYE Q3 2025 EPS Results

Actual EPS
-$2.56
Consensus EPS
-$2.51
Beat/Miss
Missed by -$0.05
One Year Ago EPS
-$0.80

SKYE Q3 2025 Revenue Results

Actual Revenue
$0
Expected Revenue
$0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2025
Date
11/10/2025
Time
After Close
Conference Call
Monday, November 10, 2025
SKYE Upcoming Earnings

Skye Bioscience's next earnings date is estimated for March 25, 2027, based on past reporting schedules.

Q3 2025 Earnings Call Audio

SKYE Q3 2025 Earnings Call
0:00 / 0:00

Q3 2025 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2025 Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 10, 2025|% Change Since:-90.93%|
Earnings Call Sentiment|Neutral

The earnings call presented a mixed picture with strong financial health and promising Phase 2a study results highlighting the potential of Nimazumab in combination with semaglutide. However, increased R&D expenses, a larger net loss, concerns about monotherapy efficacy, and limited study enrollment were notable challenges.

Company Guidance

In the Skye Bioscience, Inc. third-quarter 2025 earnings call, the company provided detailed guidance on its financial and clinical development milestones. Key financial highlights included ending the quarter with $35.3 million in cash and equivalents, with expectations to fund operations into 2027. R&D expenses increased to $9.4 million from $4.9 million in the previous year due to ongoing clinical trials, including those for Nolasimab and Nimazumab. Notably, the company reported a net loss of $12.8 million, attributed partly to non-cash share-based compensation expenses. Clinical updates focused on the promising results from the Phase 2a CBEYOND study, showing a 3% additional weight loss with Nimazumab plus semaglutide compared to semaglutide alone, with a significant p-value of 0.0372. The study also demonstrated improvements in lean to fat mass ratio and reduced waist circumference, with retention strong in the extension study. The company is advancing Nimazumab's dose concentration strategy and plans to evaluate higher doses in future studies, keeping scalability and patient convenience in focus.

  • Strong Financial PositionSkye Bioscience ended the third quarter with cash and cash equivalents totaling $35.3 million, which is expected to fund operations and key clinical milestones into 2027.
  • Successful Phase 2a Study ResultsThe Phase 2a CBEYOND study showed synergistic efficacy with Nimazumab plus semaglutide, achieving approximately 3% additional weight loss at 26 weeks with a p-value of 0.0372, nearly a 30% improvement.
  • Positive Safety ProfileNimazumab demonstrated a positive safety signal with no neuropsychiatric signals or additive GI burden.
  • Durability of Weight LossIn a 12-week post-treatment follow-up, Nimazumab plus semaglutide showed significantly less weight regain (18% vs. 50% in semaglutide alone), with a p-value of 0.006.
  • Encouraging KOL FeedbackKey opinion leaders have responded positively to the combination data, emphasizing the potential for dosing holidays without significant weight regain.

SKYE Earnings History

SKYE earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 25, 20272026 (Q4)―--0.36――
Nov 05, 20262026 (Q3)-0.770.01-2.56100.55% (+2.57)
Aug 14, 20262026 (Q2)-1.91-2.16-3.5238.64% (+1.36)
May 11, 20262026 (Q1)-2.47-2.56-2.24-14.29% (-0.32)
Mar 10, 20262025 (Q4)-2.38-2.88-1.92-50.00% (-0.96)
Nov 10, 20252025 (Q3)-2.51-2.56-0.8-220.00% (-1.76)
Aug 07, 20252025 (Q2)-2.56-3.52-1.6-120.00% (-1.92)
May 08, 20252025 (Q1)-2.30-2.24-1.44-55.56% (-0.80)
Mar 20, 20252024 (Q4)-2.23-1.92-2.8833.33% (+0.96)
Nov 07, 20242024 (Q3)-2.00-0.80-25.3696.85% (+24.56)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed